Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
24 results
  1. Excluded Studies - Core Needle and Open Surgical Biopsy for Diagnosis of Breast Lesions - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK246888
    ... Urruzola J, et al. Riesgo de invasión en carcinoma in situ de mama diagnosticado por biopsia ... breast cancer]. Zhonghua Zhong Liu Za Zhi. 2012 Oct; ...
  2. Breast Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65744
    ... HS, et al.: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379 (22): ... et al.: Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast ... patients with advanced breast cancer treated with doxorubicin-containing therapy. J ...
  3. Genetics of Breast and Gynecologic Cancers (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65767
    ... recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non- ...
  4. Articles Excluded at Full-Text Screening by Reason - Progression-Free Survival: What Does It Mean for Psychological ... 
    https://www.ncbi.nlm.nih.gov/books/NBK137765
    ... 772. Efficacy of Biological Agents (BA) in metastatic Triple Negative Breast ... cell carcinoma: Indirect comparison analysis. Leung HW, Chan AL. Level: ...
  5. Detailed Methods - Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A ... 
    https://www.ncbi.nlm.nih.gov/books/NBK545871
    ... for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar ... al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA ...
  6. Childhood Breast Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK547383
    ... adolescents and young adult (AYA) patients had more triple-negative breast cancer (TNBC) or HER2-positive (HER2+) cancer than did adult patients. In addition, AYA patients aged 15 to 29 years had more advanced disease and TNBC or HER2+ disease than did ...
  7. Breast Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65969
    ... being studied for the treatment of patients with triple-negative breast cancer. Talazoparib is a PARP inhibitor used to treat patients with mutations in the BRCA1 or BRCA2 genes and HER2 negative breast cancer that is locally advanced or has spread to other parts of the ...
  8. Appendices - Early and locally advanced breast cancer: diagnosis and management - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK541684
    ... Overall and disease free survival for people with triple negative breast cancer View in own window Parameter Overall ... Table 41 Base case results for people with triple-negative breast cancer View in own window Strategy Cost ...
  9. Breast Cancer Treatment During Pregnancy (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65716
    ... be described as triple negative or triple positive. Triple negative . If the breast cancer cells do not have ... HER2 receptors, the cancer cells are called triple negative. Triple positive . If the breast cancer cells do have ...
  10. Results - Breastfeeding Programs and Policies, Breastfeeding Uptake, and Maternal Health Outcomes in Developed ... 
    https://www.ncbi.nlm.nih.gov/books/NBK525108
    ... defined by two hormone receptor subtypes: luminal and triple-negative (low SOE). We rated the evidence as insufficient ( ... HER2+/−), (2) HER2 (HR− and HER2+), or (3) triple negative (HR− and HER2−). All 11 included studies, except ...
previous · 1 · 2 · 3 · next